After announcing acquisition plans at the beginning of 2025, immunotherapeutics biotech Hookipa Pharma has decided not to buy rare disease company Poolbeg Pharma. Jan. 2, Hookipa inked a ...

Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg and the announcement on 30 January 2025 regarding the PUSU ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange ...

HOOKIPA Pharma Inc. announced that it will not proceed with a planned all-share acquisition of Poolbeg Pharma plc, as discussed in previous communications. This decision follows non-binding ...

HOOKIPA Pharma Inc. (NASDAQ:HOOK), a biopharmaceutical company, announced today that it has decided not to proceed with the acquisition of Poolbeg Pharma plc. This decision follows a previous ...

Hookipa Pharma said it no longer intended to make an offer for U.K. pharmaceutical company Poolbeg. Both companies previously agreed to extend the deadline for Hookipa to either make an offer for ...

Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg and the announcement on 30 January 2025 regarding the PUSU ...

Further to the 2.4 announcement on 2 January 2025 on the potential combination of Poolbeg Pharma ("Poolbeg" or the "Company") and HOOKIPA Pharma Inc ("HOOKIPA"), the Board of Poolbeg announces that it ...

HOOKIPA Pharma Inc. (NASDAQ:HOOK), a biopharmaceutical company, announced today that it has decided not to proceed with the acquisition of Poolbeg Pharma plc. This decision follows a previous ...